Cancer Immunology, Immunotherapy

, Volume 67, Issue 7, pp 1177–1178 | Cite as

Interferon-α2b-induced STAT3 suppression in myeloid-derived suppressor cells in mycosis fungoides

  • Larisa J. Geskin
  • Oleg E. Akilov
  • Michael K. Schowalter
  • Louis D. FaloJr.
Letter to the Editors



This work was supported by Research Center Grants for Specialized Programs of Research Excellence of (P50CA121973) of National Institute of Health, Clinical and Translational Science and M01 Award of National Center for Research Resources.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.


  1. 1.
    Pileri A, Agostinelli C, Quaglino P, Patrizi A, Pimpinelli N (2018) The role of myeloid derived suppressor cell in mycosis fungoides: a commentary. Cancer Immunol Immunother. PubMedCrossRefGoogle Scholar
  2. 2.
    Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162–174. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Blank VC, Pena C, Roguin LP (2010) STAT1, STAT3 and p38MAPK are involved in the apoptotic effect induced by a chimeric cyclic interferon-alpha2b peptide. Exp Cell Res 316(4):603–614. CrossRefPubMedGoogle Scholar
  4. 4.
    Geskin LJ, Akilov OE, Kwon S, Schowalter M, Watkins S, Whiteside TL, Butterfield LH, Falo LD Jr (2018) Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome. Cancer Immunol Immunother 67(3):423–434. CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Larisa J. Geskin
    • 1
    • 2
  • Oleg E. Akilov
    • 1
  • Michael K. Schowalter
    • 1
  • Louis D. FaloJr.
    • 1
  1. 1.Department of DermatologyUniversity of PittsburghPittsburghUSA
  2. 2.Department of DermatologyColumbia UniversityNew YorkUSA

Personalised recommendations